The landscape of clinical trials and real-world application of
ivermectin for both Covid and cancer has been a mosaic of varied outcomes. Clinical trials, the bedrock of medical validation, are vigorously exploring the efficacy and safety profile of ivermectin in these complex conditions. Each study aims to shed light on the potential of ivermectin to alter the course of treatment paradigms significantly. In the context of Covid, early trials sparked interest by suggesting potential benefits, yet subsequent larger and more controlled studies have yielded a spectrum of results, underscoring the necessity for further investigation.